多西他赛联合吉西他滨治疗转移性乳腺癌效果观察

目的观察评价多西他赛联合吉西他滨治疗转移性乳腺癌的近期疗效及安全性。方法选择有可评价病灶的转移性乳腺癌患者36例，以多西他赛75mg／m2，吉西他滨1．0g／m2 iv·d1，8，方案治疗4—6周期后进行疗效及毒副反应分析。结果36例中，CR1例（2．8％），PR19例（52．8％），总有效率（CR＋PR）为55．6％，此外SD9例（25．0％），PD7例（19．4％）。中位随访时间7个月，中位无进展生存期为7．68个月，主要毒副反应为骨髓抑制、皮疹、恶心及呕吐等，仅有1例出现严重骨髓抑制，且经处理后可继续化疗。结论多西他赛联合吉西他滨在治疗晚期转移性乳腺癌方面有较好疗效，不良反应可耐受，是一种患者可接受的治疗方法。

Effect of gemcitabine combined with docetaxel on metastatic breast cancer patients

Aim To observe the effect and safty of gemcitabine in combination with docetaxel on patients with metastatic breast cancer. Methods The results of 36 patients with metastatic breast cancer treated with docetaxel 75mg/m2, gemcitabine 1.0/m2dl,8 for 4 to 6 cycles were observed. Results Of 36 chosen cases,the completely responded rate was 2.8% （1/36） and partial responded rate was 52.8% （19/36） with a the total response rate （CR＋PR） of 55.6%. in addition, the median progression-free survival was 7.68 months. The major adverse reactions were myelosuppression, rash, nausea and vomiting. Conclusion The combined use of gemcibafine and docetaxel is relatively effective for treatment of patients with metastatic breast cancer with tolerated adverse events.